908355-83-9

Basic information

• Product Name: 7-bromobenzo[d]thiazole-2-thiol
• Synonyms: 7-bromobenzo[d]thiazole-2-thiol;7-Bromo-2-mercaptobenzothiazole;7-broMo-1,3-benzothiazole-2-thiol;7-bromobenzo[d]thiazole-2(3H)-thione
• CAS NO: 908355-83-9
• Molecular Formula: C7H4BrNS2
• Molecular Weight: 246.15
• Product Categories: CHIRAL CHEMICALS
• Mol File: 908355-83-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 347.63 °C at 760 mmHg
• Flash Point: 164.041 °C
• Appearance: /
• Density: 1.933g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.828
• PKA: 9.22±0.20(Predicted)
• CAS DataBase Reference: 7-bromobenzo[d]thiazole-2-thiol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromobenzo[d]thiazole-2-thiol(908355-83-9)
• EPA Substance Registry System: 7-bromobenzo[d]thiazole-2-thiol(908355-83-9)

Safety Data

• Hazardous Substances Data: 908355-83-9(Hazardous Substances Data)

Usage

General Description

7-bromobenzo[d]thiazole-2-thiol is a chemical compound with the molecular formula C7H4BrNS2. It is a thiazole derivative that contains a bromine atom and a sulfur atom. 7-bromobenzo[d]thiazole-2-thiol is commonly used in organic synthesis for the preparation of various pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, such as antimicrobial and antifungal properties. Additionally, 7-bromobenzo[d]thiazole-2-thiol has been utilized in materials science and organic electronics for the development of novel functional materials. Overall, this compound has a wide range of applications in the fields of chemistry, medicine, and materials science.

InChI:InChI=1/C7H4BrNS2/c8-4-2-1-3-5-6(4)11-7(10)9-5/h1-3H,(H,9,10)

Upstream product

• 58534-94-4 2-fluoro-3-bromonitrobenzene 
• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 140-89-6 potassium ethyl xanthogenate 

Relevant articles and documents

Discovery of selective fragment-sized immunoproteasome inhibitors

Proteasomes contribute to maintaining protein homeostasis and their inhibition is beneficial in certain types of cancer and in autoimmune diseases. However, the inhibition of the proteasomes in healthy cells leads to unwanted side-effects and significant effort has been made to identify inhibitors specific for the immunoproteasome, especially to treat diseases which manifest increased levels and activity of this proteasome isoform. Here, we report our efforts to discover fragment-sized inhibitors of the human immunoproteasome. The screening of an in-house library of structurally diverse fragments resulted in the identification of benzo[d]oxazole-2(3H)-thiones, benzo[d]thiazole-2(3H)-thiones, benzo[d]imidazole-2(3H)-thiones, and 1-methylbenzo[d]imidazole-2(3H)-thiones (with a general term benzoXazole-2(3H)-thiones) as inhibitors of the chymotrypsin-like (β5i) subunit of the immunoproteasome. A subsequent structure-activity relationship study provided us with an insight regarding growing vectors. Binding to the β5i subunit was shown and selectivity against the β5 subunit of the constitutive proteasome was determined. Thorough characterization of these compounds suggested that they inhibit the immunoproteasome by forming a disulfide bond with the Cys48 available specifically in the β5i active site. To obtain fragments with biologically more tractable covalent interactions, we performed a warhead scan, which yielded benzoXazole-2-carbonitriles as promising starting points for the development of selective immunoproteasome inhibitors with non-peptidic scaffolds.